Firstly, the anti-Fzd7 monoclonal antibody targets a range of Frizzled receptors and has shown anti-tumor efficacy in a series of preclinical tumor models including pancreas, breast, and lung cancer [104]. Here, FZD7 is linked to neoplasm.